Clinical and biochemical improvement following low-dose intravenous iron therapy in a patient with erythropoietic protoporphyria

British Journal of Haematology

Volumn 163, Issue 2, 2013, Pages 289-291

  Bentley, Douglas P ^a   Meek, Elizabeth M ^a  

^a Spire Cardiff Hospital   (United Kingdom)

Author keywords

Depletion of intracellular free erythrocyte protoporphyrin; Erythropoietic Protoporphyria; Low dose intravenous iron therapy

Indexed keywords

ERYTHROCYTE PROTOPORPHYRIN; ERYTHROPOIETIN; FERRITIN; FERROCHELATASE; HEMOGLOBIN; IRON; IRON SACCHARATE; PROTOPORPHYRIN;

ADULT; CASE REPORT; ERYTHROCYTE COUNT; ERYTHROPOIETIC PROTOPORPHYRIA; FECH GENE; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON BLOOD LEVEL; LETTER; LOW DRUG DOSE; MALE; NUCLEIC ACID BASE SUBSTITUTION; PHOTOSENSITIVITY; PRIORITY JOURNAL; SOLAR RADIATION;

DEPLETION OF INTRACELLULAR FREE ERYTHROCYTE PROTOPORPHYRIN; ERYTHROPOIETIC PROTOPORPHYRIA; LOW-DOSE INTRAVENOUS IRON THERAPY;

ADMINISTRATION, INTRAVENOUS; FERRIC COMPOUNDS; HUMANS; MALE; PROTOPORPHYRIA, ERYTHROPOIETIC; SUCROSE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84884974454     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12485     Document Type: Letter

References (8)

1. Crooks, D.R., Ghosh, M.C., Haller, R.G., Tong, W.-H. & Rouault, T.A. (2010) Posttranslational stability of the heme biosynthetic enzyme ferrochelatase is dependent on iron availability and intact iron-sulphur cluster assembly machinery. Blood, 115, 860-869.
2. Delaby, C., Lyoumi, S., Decamp, S., Martin-Schmitt, C., Gouya, L., Deybach, J.C., Beaumont, C. & Puy, H. (2009) Excessive erythrocyte PP1X influences the hematologic status and iron metabolism in patients with dominant erythropoietic protoporphyria. Cellular and Molecular Biology, 55, 45-52.
3. Gordeuk, V.R., Brittenham, G.M., Hawkins, C.W., Mukhtar, H. & Bickers, D.R. (1968) Iron therapy for hepatic dysfunction in erythropoietic protoporphyria. Annals of Internal Medicine, 105, 27-31.
4. Gouya, L., Puy, H., Robreau, A.M., Bourgeois, M., Lamoril, J., Da Silva, V., Grandchamp, J.C. & Deybach, J.C. (2002) The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH. Nature Genetics, 30, 27-28.
5. Holme, S.A., Worwood, M., Anstey, A.V., Elder, G.H. & Badminton, M.N. (2007a) Erythropoiesis and iron metabolism in dominant Erythropoietic Protoporphyria. Blood, 110, 4108-4110.
6. Holme, S.A., Thomas, C.L., Whatley, S.D., Bentley, D.P., Anstey, A.V. & Badminton, M.N. (2007b) Symptomatic response of Erythropoietic Protoporphyria to iron supplementation. Journal of the American Academy of Dermatology, 56, 1070-1072.
7. Milligan, A., Graham-Brown, R.A.C., Sarkany, I. & Baker, H. (1988) Erythropoietic protoporphyria exacerbated by oral iron therapy. British Journal of Dermatology, 119, 63-66.
8. Walters, G.O., Miller, T.M. & Worwood, M. (1973) Serum ferritin concentration and iron stores in normal subjects. Journal of Clinical Pathology, 26, 770-772.